(0.29%) 5 114.69 points
(0.30%) 38 355 points
(0.31%) 15 977 points
(-0.94%) $83.06
(5.77%) $2.03
(0.37%) $2 356.00
(0.42%) $27.65
(3.99%) $958.85
(-0.22%) $0.933
(-0.39%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 6.31%
@ $4.14
発行日: 14 2月 2024 @ 23:30
リターン: 14.37%
前回のシグナル: 2月 13 - 04:00
前回のシグナル:
リターン: -5.91 %
Live Chart Being Loaded With Signals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs...
Stats | |
---|---|
本日の出来高 | 395 181 |
平均出来高 | 2.36M |
時価総額 | 272.44M |
EPS | $0 ( 2024-02-07 ) |
次の収益日 | ( $0.0500 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 118.38 |
ATR14 | $0.00400 (0.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-04 | Williams Timothy | Sell | 8 147 | Common Stock |
2024-03-05 | Williams Timothy | Sell | 8 941 | Common Stock |
2024-03-04 | Wijkstrom Joakim | Sell | 7 498 | Common Stock |
2024-03-05 | Wijkstrom Joakim | Sell | 9 229 | Common Stock |
2024-03-04 | Polymeropoulos Mihael Hristos | Sell | 30 884 | Common Stock |
INSIDER POWER |
---|
66.74 |
Last 99 transactions |
Buy: 3 050 635 | Sell: 650 292 |
ボリューム 相関
Vanda Pharmaceuticals Inc 相関
10 最も正の相関 | |
---|---|
GOSS | 0.944 |
THTX | 0.944 |
PTPI | 0.938 |
VORB | 0.931 |
TRVN | 0.929 |
LQDT | 0.929 |
TIVC | 0.928 |
XFOR | 0.927 |
SIGA | 0.925 |
CREG | 0.922 |
10 最も負の相関 | |
---|---|
RXDX | -0.952 |
AUPH | -0.951 |
POWL | -0.932 |
EZGO | -0.932 |
AVAC | -0.93 |
SUMR | -0.929 |
ALXN | -0.924 |
EMLD | -0.921 |
TCMD | -0.92 |
AVEO | -0.919 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Vanda Pharmaceuticals Inc 相関 - 通貨/商品
Vanda Pharmaceuticals Inc 財務諸表
Annual | 2023 |
収益: | $192.64M |
総利益: | $175.75M (91.23 %) |
EPS: | $0.0437 |
FY | 2023 |
収益: | $192.64M |
総利益: | $175.75M (91.23 %) |
EPS: | $0.0437 |
FY | 2022 |
収益: | $254.38M |
総利益: | $230.10M (90.45 %) |
EPS: | $0.110 |
FY | 2021 |
収益: | $268.68M |
総利益: | $243.05M (90.46 %) |
EPS: | $0.610 |
Financial Reports:
No articles found.
Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。